The study investigated the impact of adenoma detection rate (ADR), a key quality metric for colonoscopy, on the identification of prevalent colorectal cancer (CRC) during colonoscopy. While ADR is known to inversely correlate with post-colonoscopy CRC, its association with detecting existing CRC at the time of the procedure was less clear.
The study investigated the impact of adenoma detection rate (ADR), a key quality metric for colonoscopy, on the identification of prevalent colorectal cancer (CRC) during colonoscopy. While ADR is known to inversely correlate with post-colonoscopy CRC, its association with detecting existing CRC at the time of the procedure was less clear. Using data from a large national colonoscopy registry, the researchers analyzed both screening colonoscopies and those conducted after abnormal fecal test results.
The primary aim was to assess the relationship between individual endoscopists' ADR and the likelihood of identifying CRC present during the procedure. Secondary analyses examined related quality indicators, such as detection of sessile serrated lesions and advanced precancerous lesions, while considering patient demographics, procedural factors, and endoscopist-specific variables.
The findings revealed a strong positive association between higher ADR and increased detection of prevalent CRC in both screening and follow-up colonoscopies. Endoscopists with lower ADRs consistently missed more cancers, regardless of their ability to detect sessile serrated lesions. Detection of advanced precancerous lesions also mirrored ADR patterns, suggesting overlapping skills in identifying adenomas and invasive cancers.
The study concluded that many post-colonoscopy CRCs might arise from cancers missed during the initial examination, not just from undetected precursor lesions progressing over time. These results underscore the importance of maintaining high ADRs and enhancing colonoscopy quality improvement initiatives. Improving ADR can lead to better recognition of early-stage cancers and subtle neoplastic lesions, ultimately reducing the burden of CRC.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.